Celyad Oncology SA (NASDAQ:CYAD – Get Rating)'s share price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.88 and traded as low as $1.79. Celyad Oncology shares last traded at $1.79, with a volume of 8,115 shares changing hands.
Celyad Oncology Stock Down 8.7 %
The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.58 and a current ratio of 1.71. The business's 50 day simple moving average is $1.88 and its 200-day simple moving average is $2.08.
Celyad Oncology Company Profile
(Get Rating)
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
Read More
- Get a free copy of the StockNews.com research report on Celyad Oncology (CYAD)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
賽亞腫瘤股份有限公司(納斯達克代碼:Cyad-Get Rating):S的股價週四跌破50日移動均線。該股50日移動均線切入位為1.88美元,最低交易價格為1.79美元。賽亞腫瘤股票最新報1.79美元,成交量8,115股。
Celyad腫瘤學股票下跌8.7%
該公司的負債權益比率為0.05,速動比率為2.58,流動比率為1.71。該業務的50日簡單移動均線切入位在1.88美元,200日簡單移動均線切入位在2.08美元。
Celyad腫瘤學公司簡介
(獲取評級)
Celyad Oncology SA是一家臨床階段的生物製藥公司,專注於發現和開發用於癌症治療的嵌合抗原受體T(CAR-T)細胞療法。它的主要候選產品包括用於治療轉移性結直腸癌的同種異體CAR-T候選藥物Cyad-101,處於1b期臨床試驗的轉移性結直腸癌;基於短髮夾狀RNA(ShRNA)的同種異體CAR-T候選藥物,正處於治療復發/難治性多發性骨髓瘤的第一階段臨床試驗;以及正在進行第一階段臨床試驗的自體CAR-T候選藥物Cyad-02,用於治療復發或難治性急性髓系白血病和骨髓增生異常綜合徵。
閱讀更多內容
- 免費獲取StockNews.com關於Celyad腫瘤學的研究報告(CyAD)
- 耐克股票會被超賣,但仍被高估嗎?
- 美國鋁業是在第二季度業績強勁和更多股票回購之後買入的嗎?
- 皇家加勒比的寬帶合作能否推動收入增長?
- 晶片設備製造商Entigis很有潛力,但它現在可以買下嗎?
- DocuSign在報告收益時有重要的問題需要解決
接受Celyad腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Celyad Oncology和相關公司的最新新聞和分析師評級的每日簡要摘要。